Redox-responsive cisplatin nanogels for anticancer drug delivery

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Cancer Therapy

Background:

• Cisplatin is a widely used chemotherapy drug but its efficacy is limited by deactivation by glutathione (GSH) in cancer cells.
• Developing drug delivery systems that can overcome GSH-mediated resistance is crucial for improving cancer treatment outcomes.

Purpose of the Study:

• To design and create a novel glutathione (GSH) responsive nanogel for enhanced cancer therapy.
• To investigate the potential of this nanogel platform to overcome cisplatin resistance by leveraging elevated GSH levels in tumors.

Main Methods:

• A nanogel was synthesized using hyaluronan as a matrix and cisplatin as a crosslinker, encapsulating doxorubicin (Dox).
• The nanogel's drug release kinetics and cytotoxicity were evaluated under varying GSH concentrations.
• The mechanism of GSH-triggered drug release and its impact on overcoming cisplatin resistance were investigated.

Main Results:

• The prepared nanogel demonstrated a clear response to elevated GSH levels, characteristic of cancer cells.
• High GSH concentrations effectively depleted the cisplatin crosslinker, leading to enhanced release of the encapsulated doxorubicin (Dox).
• The GSH-responsive nanogel exhibited significantly boosted cytotoxicity compared to conventional delivery methods, indicating its potential to reverse cisplatin resistance.

Conclusions:

• A novel GSH-responsive nanogel platform has been successfully developed using hyaluronan and cisplatin.
• This platform effectively utilizes elevated tumorous GSH levels to trigger enhanced doxorubicin release and improve anti-cancer efficacy.
• The findings suggest a promising strategy for overcoming cisplatin resistance in cancer treatment through targeted drug delivery.